JPRN-UMIN000011294已完成2 期
Randomized Phase II Study of Regorafenib followed by Cetuximab versus Reverse SequenCe for Wild-Type KRAS Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine, Oxaliplatin, and Irinotecan (REVERECE) - Randomized Phase II Study of Sequential Treatment of Regorafenib and Cetuximab for colorectal cancer (REVERCE)
REVERCE study group0 个研究点目标入组 180 人开始时间: 2013年9月30日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Previous treatment with regorafenib, anti-EGFR antibody (cetuximab/panitumumab) or participation in clinical trial for regorafenib 2)Poorly controlled hypertension (SBP>150 mmHg or DBP >90 mmHg despite appropriate treatment) 3)Unstable angina, myocardial infarction, brain infarction, or pulmonary embolism within 6 months before entry 4)Body cavity fluid (e.g., pleural effusion, ascites, pericardial fluid) requiring intervention 5)Local or systemic active infection (grade 3 or higher according to the CTCAE ver. 4) requiring intervention 6)Symptomatic brain metastasis or brain metastasis requiring regular medication (e.g., mannitol, steroids, antiepileptic drugs) 7)Intestinal paralysis or severe gastrointestinal obstruction 8)Patients unable to swallow oral medications 9)Grade 3 or higher hemorrhage within 4 weeks before entry 10)History or clear evidence in CT scanof extensive interstitial pulmonary disease (e.g., interstitial pneumonia, pulmonary fibrosis) 11)Heart failure ≥ NYHA II 12)History of meningitis carcinomatosis, uncontrollable seizures (status epilepticus, intractable epilepsy), clinically significant mental disorder, or central nerve disorder 13)Active hepatitis B or C 14)Other active malignancies that may affect the prognosis 15)Pregnant or possibly pregnant women, lactating women, or patients unwilling to use adequate contraception 16)Uncontrolled diarrhea (diarrhea interfering with daily life despite appropriate treatment) 17)Unhealed wound (excluding central venous port), ulcer, or bone fracture 18)Any major surgery. open biopsy or traumatic injury within 28 days before enrollment (excluding the same day of the week 4 weeks ago) or colostomy without intestinal resection within 14 days before enrollment 19)Daily systemic steroid treatment (for such as collagen disease) 20)Known hypersensitivity to study drugs, study drug classes, or excipients in the formulation 21)Patients who, in the opinion of the investigator, are inappropriate for the study
研究者
相似试验
进行中（未招募）
1 期
_Patients aged =18 years old with metastatic gastro-oesophageal adenocarcinomas after failure of a first-line fluoropyrimidine and platinum-based chemotherapies.EUCTR2018-002374-46-FRICANCER89
进行中（未招募）
1 期
A randomized phase II study between regorafenib and continuing biologic treatment to multi treated patients with colorectal cancer.Patient with metastatic colorectal cancerMedDRA version: 19.0Level: LLTClassification code 10010028Term: Colorectal cancer Duke's DSystem Organ Class: 100000004864EUCTR2016-002222-37-DKHerlev og Gentofte Hospital60
进行中（未招募）
1 期
Study of Regorafenib drug for the treatment of patients with metastatic colorectal cancer (mCRC) with any RAS or BRAF gen mutation previously treated with FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) plus bevacizumabmetastatic colorectal cancerMedDRA version: 16.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2014-000703-26-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)
进行中（未招募）
1 期
Regorafenib as a single agent for treatment of patients with metastatic colorectal cancer (MCRC) who are not candidates for polychemotherapyEUCTR2013-000236-94-ESGrupo de Tratamiento de los Tumores Digestivos (TTD)
进行中（未招募）
1 期
A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN stage II-III rectAl cancerrectal cancerMedDRA version: 21.0Level: PTClassification code 10038049Term: Rectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10038050Term: Rectal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000876-40-BEInstitut Jules Bordet90